Moreover, imatinib treatment under miR-342-5p expression increased cleaved PARP-1 and reduced the anti-apoptotic protein Bcl-xL expression (Fig. 5E), as well as the observation presented in flow cytometry analysis (Fig. 5F), suggesting that miR-342-5p can increase the extent of apoptosis caused by imatinib in CML cells. The gene discussed is PARP1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.